Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01883050
Other study ID # 11-004546
Secondary ID
Status Completed
Phase N/A
First received June 4, 2013
Last updated March 21, 2018
Start date May 2013
Est. completion date June 2015

Study information

Verified date March 2018
Source Mayo Clinic
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Patients who recently suffered a heart attack will use a smart-phone/computer application during cardiac rehabilitation to reduce their risk of a future attack, their re-hospitalizations, their cost of care, and increase their quality of life.


Description:

The study will consist of two phases - an initial feasibility trial (Phase 1), followed by a randomized clinical trial (Phase 2). Once the Phase 1 trial is evaluated, Phase 2 will be implemented.

Phase 1 will consist of up to 35 participants to ensure that the software application is user-friendly, properly stores pertinent data, and has no technical glitches. All participants in Phase 1 will have access to the software application and will be asked to complete online questionnaires, at baseline and post cardiac rehab, to assess their quality of life and also their satisfaction with their care and the software application itself.

Phase 2 will consist of 65 participants. These participants will be randomized to either 1) Cardiac Rehab (CR) alone along with answering questionnaires regarding quality of life and satisfaction of care or 2) CR along with the software application and the quality of life, satisfaction of care and software application questionnaires. All participants (both Phase 1 and Phase 2) enrolled into the study will be status-post percutaneous coronary intervention (PCI). The potential participants will be asked to participate while still in the hospital and will be approached as soon as possible after agreeing to participate in CR,. The participants who enroll in Phase 2 will be randomized prior to discharge from the hospital.

All participants in Phase 1 and those in Phase 2 who randomize to the software application will be instructed on the use of either the desktop or smart-phone version of the software application. Baseline information, including participant name, date of birth, email address, and phone number, will be gathered from the participant at that time, and all characteristics will be entered by the participant and study coordinator into their own account in the application.

The study will follow all Phase 1 participants and those in Phase 2 who randomize to the software application for three months after hospital dismissal and evaluate the following:

- Weight/BMI, blood pressure, and heart rate

- Usual lab values already gathered for the participant such as lipids, Complete Blood Count (CBC), and HgbA1C

- Quality of life, disposition, and mood

- Participant compliance, satisfaction, and adherence to the application

- Re-hospitalizations, participants phone calls, and cost of care

During the second week of their CR an additional 30-60 minute educational session will be required so that the study coordinator can instruct the participant on the software application and how to use it.

We will also ask that participants "log in" to their online account at least 3-4 times weekly for important reminders, care tips, and educational materials. This will last the duration of their cardiac rehabilitation program (approximately 12 weeks). Specific examples of sections within the software application will pertain to medication adherence, diet, exercise, educational materials, and reviews of your medical profile.

Finally, we would ask that participants (all of Phase 1 and those who randomize to the software application in Phase 2) to complete online questionnaires, at baseline and post cardiac rehab. that assess their quality of life and also their satisfaction with their care and the software application itself. This will be used for both data purposes as well as in future improvements to the program. These individual surveys will take approximately 5 minutes to complete. Phase 2 study participants who do not randomize to the software application will be sent the quality of life and satisfaction of care questionnaires.


Recruitment information / eligibility

Status Completed
Enrollment 80
Est. completion date June 2015
Est. primary completion date June 2015
Accepts healthy volunteers No
Gender All
Age group 18 Years to 100 Years
Eligibility Inclusion Criteria:

- Recently underwent PCI.

- Are eligible for enrollment to the Cardiovascular Health Clinic (CVHC)

- Do not have any physical impediments to physical activity

- Do not have any impediments to physically attending the Mayo Clinic's CVHC

- They are willing to incorporate the software application into their CR

- They must have access to the internet

Exclusion Criteria:

- - They are unable or unwilling to enroll in CR

- They are unable to physically attend Mayo Clinic's CVHC CR Program

- They are unwilling to incorporate the Personal Health Assistant into their CR

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Self Monitoring Software Application
Computer Software application to track health progress after interventional surgery

Locations

Country Name City State
United States Mayo Clinic Rochester Minnesota

Sponsors (1)

Lead Sponsor Collaborator
Mayo Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Body weight Weight will be the most sensitive indicator that completion of the tasks assigned in the application lead to subsequent behavioral chance and reduction of cardiovascular risk. Baseline to 3 months
Primary Percentage of subjects who completed all tasks in the application. These data will provide the best summary of usability of the application. Baseline to 3 months
Secondary User-reported satisfaction with application. These data will provide additional insights into how users view the application interface and help us modify the design to enhance compliance. Baseline to 3 months
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Completed NCT05672862 - International Post-PCI FFR Extended Registry
Completed NCT04492423 - VerifyNow® PRUTest® Cardiovascular Population Expected Values On-Drug Study
Completed NCT01205776 - EXCEL Clinical Trial N/A
Recruiting NCT01218776 - International Survey of Acute Coronary Syndromes in Transitional Countries
Completed NCT00046410 - Comparison of the Risk of Stroke With On- Versus Off-Pump Coronary Artery Bypass Grafting N/A
Recruiting NCT04390672 - Multivessel TALENT N/A
Not yet recruiting NCT02895009 - Hemostatic Compression Patterns After Transradial Coronary Intervention N/A
Completed NCT02784873 - High Intensity Interval Training in UK Cardiac Rehabilitation Programmes N/A
Completed NCT02948517 - Time Restricted Feeding for Weight Loss and Cardio-protection N/A
Recruiting NCT02859480 - Dose-dependent Effect of Rosuvastatin on Long-term Clinical Outcomes After PCI Phase 4
Withdrawn NCT02418143 - A Study to Obtain Additional Information on the Use of CorMatrix® CanGaroo ECM® Envelope
Completed NCT02382731 - Interventions to Support Long-Term Adherence aNd Decrease Cardiovascular Events Post-Myocardial Infarction N/A
Completed NCT02510547 - Comparison of a CrossBoss First Versus Standard Wire Escalation Strategy for Crossing Coronary Chronic Total Occlusion: the "CrossBoss First" Trial Phase 4
Recruiting NCT01681381 - Evaluate Safety And Effectiveness Of The Tivoli® DES and The Firebird2® DES For Treatment Coronary Revascularization N/A
Completed NCT02248415 - Administration of Warm Blood Cardioplegia With or Without Roller Pump N/A
Recruiting NCT01207167 - Mediators of Atherosclerosis in South Asians Living in America
Completed NCT02088138 - Functional Electrical Stimulation in Cardiac Patients N/A
Completed NCT02133807 - Specific Lp(a) Apheresis for Regression of Coronary and Carotid Atherosclerosis Phase 3
Completed NCT02173067 - Anesthesia With Epinephrine in Diabetes Patients is Safe and Effective N/A